Glaxosmithkline Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 180.00 Cr
as on 09-12-2024
- Paid Up Capital ₹ 169.41 Cr
as on 09-12-2024
- Company Age 100 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 21.87 Cr
as on 09-12-2024
- Satisfied Charges ₹ 130.00 Cr
as on 09-12-2024
- Revenue 6.42%
(FY 2024)
- Profit -3.79%
(FY 2024)
- Ebitda 12.66%
(FY 2024)
- Net Worth 1.77%
(FY 2024)
- Total Assets 6.61%
(FY 2024)
About Glaxosmithkline Pharmaceuticals
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 500660 and on the National Stock Exchange(NSE) under GLAXO.
The Corporate was formerly known as British Drug Houses (India) Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 180.00 Cr and a paid-up capital of Rs 169.41 Cr.
The company currently has active open charges totaling ₹21.87 Cr. The company has closed loans amounting to ₹130.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Glaxosmithkline Pharmaceuticals Limited India are Ajay Nadkarni as COMPANY SECRETARY and Juby Chandy as Cfo. Renu Karnad, Sundaram Damodarannair, Manu Anand, and Six other members serve as directors at the Company.
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Glaxosmithkline Pharmaceuticals?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bhushan Akshikar  | Managing Director | 01-Dec-2022 | Current |
| Ajay Nadkarni | Company Secretary | 01-Nov-2001 | Current |
| Juby Chandy | CFO | 01-Apr-2022 | Current |
Board Members(8)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sunitha Maheshwari | Director | 18-May-2020 | Current |
| Sundaram Damodarannair | Director | 27-Jul-2009 | Current |
Subesh Williams  | Director | 07-Apr-2017 | Current |
| Renu Karnad | Director | 01-Apr-2019 | Current |
| Pradeep Bhide | Director | 28-Oct-2010 | Current |
| Manu Anand | Director | 16-May-2022 | Current |
Financial Performance and Corporate Structure Insights of Glaxosmithkline Pharmaceuticals.
Glaxosmithkline Pharmaceuticals Limited, for the financial year ended 2024, experienced modest growth in revenue, with a 6.42% increase. The company also saw a slight decrease in profitability, with a 3.79% decrease in profit. The company's net worth moved up by a moderate rise of 1.77%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Glaxosmithkline Pharmaceuticals?
In 2023, Glaxosmithkline Pharmaceuticals had a promoter holding of 75.00% and a public holding of 25.01%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Schneider Electric India Private LimitedActive 29 years 9 monthsSundaram Damodarannair is a mutual person
Credila Financial Services LimitedActive 18 years 10 monthsSundaram Damodarannair is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Hongkong And Shanghai Banking Corporation Ltd. Creation Date: 13 Jul 1989 | ₹21.87 Cr | Open |
Uti Bank Ltd. Creation Date: 20 Sep 2004 | ₹130.00 Cr | Satisfied |
How Many Employees Work at Glaxosmithkline Pharmaceuticals?
Glaxosmithkline Pharmaceuticals has a workforce of 3458 employees as of Dec 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Glaxosmithkline Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Glaxosmithkline Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
